Allspring Global Investments Holdings LLC Has $2.91 Million Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

Allspring Global Investments Holdings LLC boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 428.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 117,088 shares of the biopharmaceutical company’s stock after acquiring an additional 94,933 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Catalyst Pharmaceuticals were worth $2,906,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Advisors Preferred LLC bought a new stake in Catalyst Pharmaceuticals in the first quarter valued at approximately $9,438,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in shares of Catalyst Pharmaceuticals by 15.1% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 66,223 shares of the biopharmaceutical company’s stock worth $1,640,000 after acquiring an additional 8,673 shares during the period. Fifth Third Bancorp boosted its stake in shares of Catalyst Pharmaceuticals by 4,708.1% during the 1st quarter. Fifth Third Bancorp now owns 28,368 shares of the biopharmaceutical company’s stock worth $702,000 after acquiring an additional 27,778 shares during the period. SkyOak Wealth LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth approximately $303,000. Finally, Kestra Advisory Services LLC increased its holdings in shares of Catalyst Pharmaceuticals by 1.9% during the 1st quarter. Kestra Advisory Services LLC now owns 39,901 shares of the biopharmaceutical company’s stock worth $988,000 after acquiring an additional 742 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

CPRX has been the topic of several research reports. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Robert W. Baird downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $35.00 to $31.50 in a report on Friday, May 8th. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.49 on Friday. The company has a market cap of $3.86 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74. The company has a 50 day moving average of $31.39 and a 200-day moving average of $27.30. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $32.56.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).